title: Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
abstract: BACKGROUND
  Highly active antiretroviral therapy (HAART) has improved the prognosis of HIV-infected patients. We studied the changes in the incidence and prognosis of cytomegalovirus (CMV) disease preceding and during the first few years of HAART in a clinic cohort.
  
  
  METHODS
  All patients with CMV disease diagnosed between 1993 and 1999 from a clinic cohort in Cologne, Germany, were included. The patients were followed until death or until December 31, 2001. The time period from 1993-1996 was classified as pre-HAART, the period from 1997-1999 as the HAART era. Survival was analyzed with a Cox-proportional hazard model.
  
  
  RESULTS
  From a total of 1,279 HIV-infected patients, 127 patients with CMV disease were enrolled. The incidence of CMV disease declined rapidly and significantly from 7.34 cases per 100 patient years (py) in the pre-HAART era to 0.75 cases per 100 py in the HAART era. The median survival time in the pre-HAART era was 9.5 months; the median survival was not yet reached at 4 years of follow-up in the HAART era. The only risk factors influencing survival were CD4-cell count and antiretroviral therapy before and after diagnosis of CMV disease. Treatment naive patients had a better prognosis than pretreated patients and patients treated with triple combination therapy survived longer than patients with other treatment modalities.
  
  
  CONCLUSIONS
  A rapid decline in the incidence of new CMV manifestations and a better prognosis of patients with CMV disease, especially if they were treatment naive and treated with triple combination therapy, were observed in the HAART era.
authors.affiliation: Klinik und Poliklinik I für Innere Medizin, Universitätsklinikum Regensburg, 93042 Regensburg, Germany. bernd.salzberger@klinik.uni-r.de
authors.forename: B
authors.initials: B
authors.lastname: Salzberger
authors.forename: P
authors.initials: P
authors.lastname: Hartmann
authors.forename: F
authors.initials: F
authors.lastname: Hanses
authors.forename: B
authors.initials: B
authors.lastname: Uyanik
authors.forename: O A
authors.initials: OA
authors.lastname: Cornely
authors.forename: A
authors.initials: A
authors.lastname: Wöhrmann
authors.forename: G
authors.initials: G
authors.lastname: Fätkenheuer
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D005858:Germany / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate